Overexpression and elevated plasma level of tumor-associated antigen 90K/Mac-2 binding protein in colorectal carcinoma

被引:16
作者
Wu, Chih-Ching [1 ,2 ]
Huang, Yu-Shan [1 ,2 ]
Lee, Li-Yu [3 ]
Liang, Ying [2 ]
Tang, Rei-Ping [4 ]
Chang, Yu-Sun [2 ]
Hsieh, Ling-Ling [5 ]
Yu, Jau-Song [1 ,6 ]
机构
[1] Chang Gung Univ, Prote Core Lab, Tao Yuan, Taiwan
[2] Chang Gung Univ, Mol Med Res Ctr, Tao Yuan, Taiwan
[3] Chang Gung Mem Hosp, Dept Pathol, Tao Yuan, Taiwan
[4] Chang Gung Mem Hosp, Dept Surg, Colorectal Sect, Tao Yuan, Taiwan
[5] Chang Gung Univ, Dept Publ Hlth, Tao Yuan, Taiwan
[6] Chang Gung Univ, Dept Cell & Mol Biol, Tao Yuan, Taiwan
关键词
Biomarker; Colorectal carcinoma; Mac-2BP; Secretome; TAA90K;
D O I
10.1002/prca.200800080
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The cancer cell secretome may contain potentially useful biomarkers. Previously, we have analyzed the colorectal carcinoma (CRC) cell secretome. In this study, tumor-associated antigen 90K (TAA90K)/Mac-2 binding protein (Mac-2BP), one of the CRC cell secreted proteins, was chosen for evaluation as a potential CRC biomarker because its mRNA level was also found to be significantly elevated in CRC tissues and in a more metastatic CRC cell line from the analysis of two public domain array-based datasets. Immunohistochemical analysis of 241 CRC specimens showed that TAA90K/Mac-2BP was positively detected in 52.7% of the tumors, but weakly or not detected in over 95% of the adjacent nontumor epithelial cells. The plasma TAA90K/Mac-2BP levels were significantly higher in CRC patients (N = 280) versus healthy controls (N = 147) (7.77 +/- 3.49 vs. 5.72 +/- 2.67 mu g/mL, p < 0.001). Moreover, combination of TAA90K/Mac-2BP and carcinoembryonic antigen (CEA) could outperform CEA alone in discriminating CRC patients from healthy persons in this case-control study. Our results collectively indicate that analysis of cancer cell secretome is a feasible strategy for identifying cancer biomarker candidates, and the TAA90K/Mac-2BP may be a potential CRC biomarker.
引用
收藏
页码:1586 / 1595
页数:10
相关论文
共 37 条
[1]  
Alessandro Riccardo, 2005, Clin Colorectal Cancer, V4, P396, DOI 10.3816/CCC.2005.n.012
[2]  
*AM SOC CLIN ONC, 1998, J CLIN ONCOL, V16, P793
[3]  
Chen Li-Tzong, 2004, Clin Colorectal Cancer, V4, P196, DOI 10.3816/CCC.2004.n.020
[4]  
Chen THH, 1999, CANCER, V86, P1116, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1116::AID-CNCR4>3.0.CO
[5]  
2-D
[6]   Site-specific methylation of CpG nucleotides in the hTERT promoter region can control the expression of hTERT during malignant progression of colorectal carcinoma [J].
Choi, Jee-Hye ;
Park, Soo Hyun ;
Park, Jina ;
Park, Borae G. ;
Cha, Seong-Jae ;
Kong, Kwang-Hoon ;
Lee, Kwang-Ho ;
Park, Ae Ja .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 361 (03) :615-620
[7]  
Fernandez-Fernandez L, 1995, Eur J Surg Oncol, V21, P388, DOI 10.1016/S0748-7983(95)92516-3
[8]   Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer [J].
Gorelik, E ;
Landsittel, DP ;
Marrangoni, AM ;
Modugno, F ;
Velikokhatnaya, L ;
Winans, MT ;
Bigbee, WL ;
Herberman, RB ;
Lokshin, AE .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (04) :981-987
[9]   MUCINOUS CARCINOMA - JUST ANOTHER COLON CANCER [J].
GREEN, JB ;
TIMMCKE, AE ;
MITCHELL, WT ;
HICKS, TC ;
GATHRIGHT, JB ;
RAY, JE .
DISEASES OF THE COLON & RECTUM, 1993, 36 (01) :49-54
[10]   THE MEANING AND USE OF THE AREA UNDER A RECEIVER OPERATING CHARACTERISTIC (ROC) CURVE [J].
HANLEY, JA ;
MCNEIL, BJ .
RADIOLOGY, 1982, 143 (01) :29-36